Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BOOG 2017-03: Endocrine Therapy Plus CDK 4/6 Inhibition in First- or Second-line for Hormone Receptor Positive Advanced Breast Cancer - the SONIA Study

Trial Profile

BOOG 2017-03: Endocrine Therapy Plus CDK 4/6 Inhibition in First- or Second-line for Hormone Receptor Positive Advanced Breast Cancer - the SONIA Study

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Palbociclib (Primary) ; Ribociclib (Primary) ; 18F-fluoroestradiol; Anastrozole; Estradiol dehydrogenase inhibitors; Fulvestrant; Goserelin; Goserelin; Letrozole; Leuprorelin; Leuprorelin; Oxacillin; Oxacillin
  • Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use
  • Acronyms SONIA
  • Most Recent Events

    • 06 Jun 2023 Primary endpoint PFS2 has not been met according to result presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2023 Results (data cut off 1 December 2022) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 27 Feb 2023 Planned End Date changed from 1 Jan 2023 to 1 Dec 2025.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top